06-21-05

Ifw

**QOCKET NO.: AM100201 P1/WYNC-0734** 

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

JUN 2 0 2005

Jonathan L. Gross and Gary P. Stack

Confirmation No.: 6426

Application No.: 10/618,947

Group Art Unit: 1624

Filing Date: July 14, 2003

Examiner: Zachary C. Tucker

For: ANTIDEPRESSANT AZEHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO [2,3-f] QUINOXALINE

EXPRESS MAIL LABEL NO: EV 632381647 US

DATE OF DEPOSIT: June 20, 2005

71EAP35397P44A77

MS Amendment MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: REPLY TRANSMITTAL LETTER A Preliminary Amendment.  $\boxtimes$ An Amendment Responsive to the Office Action Dated March 22, 2005. An Amendment Supplemental to the Paper filed A Substitute Specification (pages 1 -) in clean form. A substitute specification (pages 1 -) with markings. An Abstract is enclosed. replacement sheets of drawings are enclosed comprising figures Request is hereby made to accept black and white photograph(s) in this case, as they are the only practicable medium for illustrating the claimed invention. One (1) set of black and white photographs comprising figure(s) is submitted herewith. Petition is hereby made to accept drawing(s)/photograph(s) in this case.

Three (3) sets of color drawing(s)/photograph(s) and black and white photocopy that accurately depicts to the extent possible, the subject matter shown in the color drawing(s)/photograph(s), are enclosed, comprising figures An amendment to the first paragraph in that portion of the Brief Description of the Drawings is also enclosed herewith advising that the patent contains at least one drawing/photograph in color. A Certified Copy of each of the following applications: is enclosed. An Assignee Power of Attorney is enclosed. Information Disclosure Statement. Attached Form 1449. A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith. A Terminal Disclaimer is attached.  $\boxtimes$ Appendices as follows: Boyer WF. Potential indications for the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 6 Suppl 5, 5-12 (1992) Pallanti S, Quercioli L, Ramacciotti, A. Citalopram in anorexia nervosa. Eat Weight Disord. 2(4), 216-21 (1997) Fassino S, Leombruni P, Daga G, Brustolin A, Migliaretti G, Cavallo F, Rovera G. Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol. 2002 12(5), 453-9 (2002) Other X No Additional Fee is Due. Applicant(s) has previously claimed small entity status under 37 CFR § 1.27. Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as This application is no longer entitled to small entity status. It is requested that this be noted in the files of the U.S. Patent and Trademark Office.

**PATENT** 

**DOCKET NO.: AM100201 P1/WYNC-0734** 

**DOCKET NO.: AM100201 P1/WYNC-0734** 

## **PATENT**

				SMALL	ENTITY	NOT SMAL	L ENTITY
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	1	20 (20 MINIMUM)	0	\$25 EACH	\$	\$50 EACH	\$0
INDEP. CLAIMS	1	3 (3 MINIMUM)	0	\$100 EACH	\$	\$200 EACH	\$0
FIRST PRESENTATION OF MULTIPLE DEPENDENT			\$180	\$	\$360	\$0	
ONE MONTH EXTENSION OF TIME			\$60	\$	\$120	\$0	
☐ TWO MONTH EXTENSION OF TIME			\$225	\$	\$450	\$0	
THREE MONTH EXTENSION OF TIME			\$510	\$	\$1020	\$0	
☐ FOUR MONTH EXTENSION OF TIME			\$795	\$	\$1590	\$0	
☐ FIVE MONTH EXTENSION OF TIME				\$1080	\$	\$2160	\$0
LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$0)
☐ TERMINAL DISCLAIMER				\$65	\$	\$130	\$0
☐ OTHER FEE OR SURCHARGE AS FOLLOWS:							0
TOTAL FEE DUE					\$		\$0

$\boxtimes$	Please charge any deficiency or credit any overpayment to Deposit Account 23-3050.
	Please charge Deposit Account No. 23-3050 in the amount of00. This sheet is attached in duplicate.
	The Commissioner is hereby authorized to charge any deficiency or credit any overpayment of the fees associated with this communication to Deposit Account No. 23-3050.
	Petition is hereby made under 37 CFR § 1.136(a) (fees: 37 CFR § 1.17(a)(1)-(4)) to extend the time for response to the Office Action of to and through comprising an extension of the shortened statutory period of month(s).

The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to Deposit Account 23-3050. This sheet is provided in duplicate.

Date: June 20, 2005

Registration No. 36,697

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2005 WW

**DOCKET NO.:** WYNC-0734 (AM-100201 P1)

**Application No.:** 10/618,947

Office Action Dated: March 22, 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of:

Jonathan L. Gross and Gary P. Stack

Confirmation No.: 6426

Application No.: 10/618,947

Group Art Unit: 1624

Filing Date: July 14, 2003

Examiner: Z. C. Tucker

ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF

2, 3- DIHYDRO - 1, 4- DIOXINO [2, 3-f] QUINOXALINE

EXPRESS MAIL LABEL NO: EV 632381647 US

**PATENT** 

DATE OF DEPOSIT: June 20, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## REPLY PURSUANT TO 37 C.F.R. § 1.111

	in res	ponse to the Official Action dated March 22, 2005, reconsideration is
respec	tfully re	equested in view of the amendments and/or remarks as indicated below:
		Amendments to the Specification begin on page of this paper.
	$\boxtimes$	Amendments to the Claims are reflected in the listing of the claims that begins on page 2 of this paper.
		Amendments to the Drawings begin on page of this paper and include an attached replacement sheet.
	$\boxtimes$	Remarks begin on page 3 of this paper.